Literature DB >> 3017723

Enalapril reduces the catecholamine response to exercise in patients with heart failure.

B P McGrath, L F Arnolda.   

Abstract

Increased sympathetic activity occurs in congestive heart failure and may have deleterious effects. To examine the effects of angiotensin converting enzyme (ACE) inhibition on sympathetic activity in heart failure, the noradrenaline response to exercise was measured in 18 patients given enalapril or placebo in double-blind trial. The plasma noradrenaline response to graded exercise was significantly reduced after 4 weeks on active treatment but was unchanged by placebo treatment. The rate-pressure product at maximal exercise was significantly reduced after 4 weeks in the enalapril group but unchanged in the placebo group. These results suggest that ACE inhibition reduces sympathetic activity in patients with heart failure.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3017723     DOI： 10.1007/bf00607965

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  13 in total

1.  A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma.

Authors:  H Hörtnagl; C R Benedict; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

Review 2.  Interaction between sympathetic and renin-angiotensin system.

Authors:  B G Zimmerman; E J Sybertz; P C Wong
Journal:  J Hypertens       Date:  1984-12       Impact factor: 4.844

3.  Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats.

Authors:  M J Antonaccio; L Kerwin
Journal:  Eur J Pharmacol       Date:  1980-11-21       Impact factor: 4.432

4.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

Authors:  J N Cohn; T B Levine; M T Olivari; V Garberg; D Lura; G S Francis; A B Simon; T Rector
Journal:  N Engl J Med       Date:  1984-09-27       Impact factor: 91.245

5.  Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study.

Authors:  D N Sharpe; J Murphy; R Coxon; S F Hannan
Journal:  Circulation       Date:  1984-08       Impact factor: 29.690

6.  Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats.

Authors:  O Kohlmann; M Bresnahan; H Gavras
Journal:  Hypertension       Date:  1984 Mar-Apr       Impact factor: 10.190

7.  Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure.

Authors:  G S Francis; S R Goldsmith; S M Ziesche; J N Cohn
Journal:  Am J Cardiol       Date:  1982-04-01       Impact factor: 2.778

8.  Captopril interferes with neurogenic vasoconstriction in the pithed rat by angiotensin-dependent mechanisms.

Authors:  R Hatton; D P Clough
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jan-Feb       Impact factor: 3.105

9.  Controlled trial of enalapril in congestive cardiac failure.

Authors:  B P McGrath; L Arnolda; P G Matthews; B Jackson; G Jennings; H Kiat; C I Johnston
Journal:  Br Heart J       Date:  1985-10

10.  Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril.

Authors:  M A Creager; D P Faxon; D A Weiner; T J Ryan
Journal:  Br Heart J       Date:  1985-04
View more
  9 in total

1.  Forearm vasoconstriction during dynamic leg exercise in patients with chronic heart failure.

Authors:  J J Atherton; L G Dryburgh; H L Thomson; T D Moore; K N Wright; G W Muehle; L E Fitzpatrick; M P Frenneaux
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

2.  Failure of dopexamine to maintain haemodynamic improvement in patients with chronic heart failure.

Authors:  J J Murphy; J R Hampton
Journal:  Br Heart J       Date:  1988-07

Review 3.  Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

4.  Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study.

Authors:  B Herrlin; O Nyquist; C Sylvén
Journal:  Br Heart J       Date:  1991-09

5.  Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine.

Authors:  M Bellet; P Sassano; T Guyenne; P Corvol; J Menard
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

6.  Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patients.

Authors:  C J O'Neill; A Charlett; R J Dobbs; A A Deshmukh; S G Bowes; C Weller; P W Nicholson; J S Milledge; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

7.  Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.

Authors:  A Sigurdsson; O Amtorp; T Gundersen; B Nilsson; J Remes; K Swedberg
Journal:  Br Heart J       Date:  1994-11

Review 8.  The use of angiotensin-converting enzyme inhibitors in congestive heart failure.

Authors:  J L Rouleau; C Juneau; J de Champlain
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

9.  Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure: A PRISMA-Compliant Network Meta-Analysis.

Authors:  WeiPing Sun; HaiBin Zhang; JinCheng Guo; XueKun Zhang; LiXin Zhang; ChunLei Li; Ling Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.